Grant Pickering Sells 15,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CEO Grant Pickering sold 15,000 shares of the company’s stock in a transaction dated Tuesday, April 23rd. The shares were sold at an average price of $61.92, for a total transaction of $928,800.00. Following the completion of the sale, the chief executive officer now directly owns 477,847 shares of the company’s stock, valued at approximately $29,588,286.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Grant Pickering also recently made the following trade(s):

• On Monday, March 25th, Grant Pickering sold 15,000 shares of Vaxcyte stock. The shares were sold at an average price of $66.93, for a total transaction of $1,003,950.00.
• On Friday, March 1st, Grant Pickering sold 2,616 shares of Vaxcyte stock. The shares were sold at an average price of $73.70, for a total transaction of $192,799.20.
• On Thursday, February 1st, Grant Pickering sold 2,616 shares of Vaxcyte stock. The stock was sold at an average price of $73.91, for a total transaction of $193,348.56.
• On Monday, January 29th, Grant Pickering sold 30,000 shares of Vaxcyte stock. The stock was sold at an average price of $66.03, for a total transaction of $1,980,900.00.

Vaxcyte Stock Up 1.1 %

Shares of NASDAQ:PCVX opened at $60.72 on Friday. The firm’s 50 day moving average price is $67.96 and its 200 day moving average price is $61.36. The stock has a market cap of $6.60 billion, a price-to-earnings ratio of -14.70 and a beta of 0.89. Vaxcyte, Inc. has a fifty-two week low of $41.57 and a fifty-two week high of $82.04.

Vaxcyte (NASDAQ:PCVX) last issued its earnings results on Tuesday, February 27th. The company reported ($1.82) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.93). During the same quarter in the previous year, the business earned ($0.73) EPS. On average, equities analysts anticipate that Vaxcyte, Inc. will post -4.18 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on PCVX shares. Bank of America increased their price target on shares of Vaxcyte from $67.00 to $80.00 and gave the stock a “buy” rating in a research report on Tuesday, January 2nd. Needham & Company LLC reissued a “buy” rating and set a $95.00 price target on shares of Vaxcyte in a research report on Wednesday, April 10th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a research report on Friday, January 12th. Four equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $78.50.

Hedge Funds Weigh In On Vaxcyte

A number of hedge funds have recently modified their holdings of PCVX. Parallel Advisors LLC grew its position in shares of Vaxcyte by 155.3% during the fourth quarter. Parallel Advisors LLC now owns 411 shares of the company’s stock worth $26,000 after acquiring an additional 250 shares during the last quarter. Banque Cantonale Vaudoise grew its position in shares of Vaxcyte by 96.7% during the first quarter. Banque Cantonale Vaudoise now owns 1,184 shares of the company’s stock worth $81,000 after acquiring an additional 582 shares during the last quarter. Avior Wealth Management LLC purchased a new position in shares of Vaxcyte during the third quarter worth approximately $178,000. Vanguard Personalized Indexing Management LLC purchased a new position in shares of Vaxcyte during the fourth quarter worth approximately $208,000. Finally, Rathbones Group PLC purchased a new position in shares of Vaxcyte during the third quarter worth approximately $221,000. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.